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Abstract: The selective delivery of therapeutic and imaging agents 
to tumoral cells has been postulated as some of the most important 
challenges in nanomedicine field. The cellular selectivity of 
nanocarriers is usually achieved by their surface decoration with 
targeting moieties able to recognize these cells in a specific manner. 
Neuroblastoma (NB) is the most frequent extra-cranial pedriatic 
tumor, almost incurable at advanced stages. Meta-iodo-
benzilguanidine (MIBG) is widely used for the diagnosis of this 
disease due to its strong affinity by the norepinephrine transporter 
(NET) usually overexpressed on the membrane of the malignant 
cells. Herein, a complete family of novel Y-shaped scaffolds which 
contains structural MIBG analogues covalently attached in each end 
of the Y-structure has been synthesized. The enhanced cellular 
uptake capacities of these double-targeting ligands have been 
evaluated in vitro and in vivo yielding one specific Y-shape structure 
which presents capacity to be engulfed by the malignant cells and be 
accumulated in the tumoral tissue, significantly higher than the 
structure which contains only one single targeting agent. This Y-
shaped ligand can provide a powerful tool for the current and 
treatment diagnosis of this disease.  
Neuroblastoma (NB) is the most common extra-cranial solid 
tumor in childhood. The 50% of the cases are diagnosed at late 
stages when the disease has spread throughout the entire body, 
in metastatic stage.[1] The treatment of metastatic NB (stage IV) 
is usually based on the combination of various 
chemotherapeutic agents in high doses, together with surgical 
removal of the primary tumor, only in cases of a good response 
to the initial chemotherapy. Finally, the treatment is completed 
with radiotherapy, or complementation of the initial 
chemotherapy with autologous for hematopoietic rescue and 
pre-treatment of possible residual disease with differentiating 
agents.[2] Despite this multimodal treatment, up to 60% of 
children with stage IV of NB relapse. Thus, the prognosis of 
advanced NB is very poor, which demonstrates the inability of 
the current treatment to eradicate the entire disease. NB cells 
come from the neural crest, such as precursors of the 
sympathetic nervous system.  Around 95% of NB cells present 
an overexpression of the transmembrane protein norepinephrine 
transporter (NET) being able of capturing norepinephrine 
precursors. The synthetic norepinephrine analogue meta-
iodobenzylguanidine (MIBG) selectively binds to NET receptor 
and for this reason, it is widely used for the diagnosis of NB 
when  the molecule is labeled with a radioactive iodine.[3],[4][5] 
Several structure/activity relationship (SAR) studies have 
demonstrated that benzene ring and guanidine moiety are the 
pillars for maintaining the NET binding capacity of MIBG. Thus, 
the rest of the structure admits some degree of modification 
such as substitution of the iodine for other group with different 
electro-donor / attractor character. Further, changes in the 
position of the substitution and even replacing the aromatic ring 
itself have been carried out for improving both, cell uptake and 
tumor tissue accumulation.[6-10] However, the in vivo assays did 
not yield the expected  results, being the MIBG the most active. 
Even, the incorporation of a second guanidine group in position 
4 led to a significant decrease in the internalization in NB 
cells.[11] Until now, only the incorporation of a methyl group in 
position 4 improves the retention of this molecule by the NB 
cells.[7–9,11] The MIBG analogue which contains an amino group 
instead of the iodine, meta-aminobenzylguanidine (MABG), has 
shown similar NET binding ability that MIBG. For this reason, 
MABG was  conjugated to non-radioactive fluorescence 
compounds in the near infrared  by organic spacers acting as 
image agent,[12] resulting an excellent vectorization agent that 
yields improved spatial imaging resolution in comparison to that 
obtained by SPECT. Furthermore, we previously employed 
MABG as targeting moiety for guiding nanoparticles specifically 
to neuroblastoma in murine models.[13] In this work, MABG was 
anchored on the surface of mesoporous silica nanoparticles 
(MSN) through a polyethylene glycol polymer (PEG) of 2000 Da 
of molecular weight which acted as spacer between the 
nanoparticle surface and the recognition moiety. The presence 
of this targeting group enhanced the nanoparticle uptake in NB 
cell around 4-fold. Additionally, it was found that the presence of 
this targeting group on the nanoparticle surface, led  
[a] Prof. María Vallet-Regí and Dr. Alejandro Baeza  
Dpto. Química en Ciencias Farmacéuticas. Facultad de Farmacia, 
Universidad Complutense de Madrid. Plaza Ramon y Cajal s/n. 
 Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12 ¡  
           Centro de Investigación Biomédica en Red de Bioingeniería, 
Biomateriales y Nanomedicina (CIBER-BBN) 
 Madrid, Spain 
E-mail: vallet@ucm.es; abaezaga@ucm.es 
[b]       Servicio de Inmunología. Hospital Universitario de La Princesa.  
[c] Instituto de Investigacion Sanitaria La Princesa. Diego de León, 62. 
28006 Madrid, Spain. 
[d] Dr. Manuel Ramírez, Dr. Gustavo Melen, Dr. Africa Gonzalez-
Murillo. Servicio de Hematología y Oncología Pediátrica, Hospital 
Infantil Universitario Niño Jesús, Madrid, Spain. 
 Supporting information for this article is given via a link at the end of 
the document. 
[e] Dpto. Materiales y Producción Aeroespacial, ETSI Aeronáutica y del 
Espacio, Universidad Politécnica de Madrid, 28040-Madrid, Spain. 
 
 
Manuscript Click here to access/download;Manuscript;Manuscript Revised
final version.docx
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
COMMUNICATION          
 
 
 
 
Figure 1. Fluorescein PEGylated analogues for in vitro analysis from all families of single and double targeting system. X1 and X2 = amide bond in all cases.
 
to a selective accumulation and high retention of the 
nanocarriers in the tumoral mass of a xenograft mice model 
whereas untargeted to the rapid excretion of the nanoparticles. 
This approach is based on the use of one single targeting agent 
which interacts with a membrane cell receptor overexpressed in 
the tumoral cells. Nature usually employs antibodies as 
recognition agents and these proteins present a Y-shaped 
structure able to bind to the antigens by two points instead of 
one.[14] Inspired by these natural molecules, the following two 
questions were raised to the authors;  synthetic Y-shaped 
scaffold which contains two MABG-based binding points could 
improve even more the cellular uptake within NB cells?, and the 
second question related to this first one,  which is the optimal Y-
structure that yielded the best NET-binding capacities? The 
present work describes the synthesis and biological evaluation 
of different Y-shaped scaffolds decorated with MABG analogues, 
and also with other usually employed targeting moieties, for the 
look out of improved vectorization agents which allow the 
therapeutic / imaging targeted delivery to neuroblastoma.[15] This 
Y shape promising prototype could pave the way of a safer 
delivery of chemotherapy and also for a more sensitive and 
efficient diagnosis of NB lesions.   Previous to the construction 
of Y-shape moieties, we decided to synthesize a small collection 
of MABG-based derivatives in order to select the analogue 
which yielded the higher cellular uptake in NB. These 
experiments will be essential in order to choose the best 
candidate for its introduction in the Y shape scaffold. Thus, 
different MABG analogues which carry halogens attached to the 
benzyl ring or with the amide group in meta- or para- position 
were synthesized. Then, these molecules were conjugated with 
a fluorescein-labeled polyethylene glycol (PEG) chain of 3500 
Da of molecular weight (Figure 1) The PEGylated fluorescein 
acts as fluorescent marker payload emulation which makes 
possible their tracing on in vitro assays by flow cytometry 
(fluorescein (ƛex = 492 nm; ƛem= 520 nm). Thus, the marked 
single derivates, F-PEG-S3, (m-glycinamido-benzylguanidine), 
F-PEG-S4 (p-glycinamido-benzylguanidine), F-PEG-SCl (p-
chloro-m-glycinamido-benzylguanidine ) and F-PEG-SI, (p-
glycinamido-m-iodo-benzylguanidine) ) were synthetized from 
the corresponding compounds with terminal primary alkyl amine 
group proportioned by glycine coupling. (See Supporting 
information (SI) from Scheme S1 to Scheme S5). The cellular 
uptake of these conjugates was evaluated in the NB cell line 
(NB1691-luc). Cells were incubated for 2 hours with each of 
these conjugates at 50 μg·mL-1 in culture medium, washed once 
with PBS and the well refilled with fresh medium. Finally, cells 
were incubated overnight and washed with PBS for removing 
the non-incorporated conjugate. The cellular uptake was 
measured by flow cytometry showing that the introduction of 
halogens in the benzyl ring yielded lower internalization capacity 
whereas the system which presents only one amide group (both 
in meta- and para- position) achieved the best results. After 2 
hours of incubation with the corresponding analogue the para-
amide substituted compound (S4) showed the best performance 
with 75% of cells with fluorescence inside, versus the barely 
50 % obtained by the meta- analogue (S3). Thus, para- and 
meta-amino derivatives were selected as the best systems to be 
incorporated in the Y-shaped structures. As a first approximation 
for doubling the uptake properties of the MAGB analogues, 
flexible medium length amino acid Y-shape scaffold (DF) was 
chosen as initial candidate to combine the benzylguanidine 
analogues to each other. On the other hand, other motives, were 
also tested in combination with the MABG analogues in the DF 
scaffold. DF structure is based on a two Lysine units connected 
by a peptidic bond. Both targeting agents were connected to the 
scaffold by amidation of the primary amine groups. For this aim 
succinic derivative of S3 and S4 were synthetized previously (SI, 
Scheme S6) in order to afford DF3 and DF4. Besides these 
systems, DFS3-TPP and DFS3-RGD were also synthetized. 
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DFS3-TPP was designed with the two unit peptide scaffold 
connecting the succinic S3 analogue and triphenilphosphine unit, 
that present vectorization to the mitochondria.[16],[17],[18] On the 
other hand, DFS3-RGD, was constructed with the same 
structure changing the motif for the tripeptide RGD trying to 
combine two different tumoral receptors that will be present in 
the NB tumor endothelium and cell membrane.[19] (See SI 
Scheme S12 and S13). In all cases the system have a primary 
amine group as exclusive anchoring point to link with the pre-
activated acid group from PEG, which connected to the 
corresponding payload. Similar to the mentioned analogues, a 
fluorescent moiety was anchored for following the system in in 
vitro experiments (F-PEG-DFX). Figure S7 from SI shows how 
double systems DF3 and DF4 present more than 90 % of 
cellular uptake at 50 µg.mL-1and even at 25 µg.mL-1. Following 
the tendency, the single S4 showed an excellent results with a 
75 %, leading the rest of single ligands which presented an 
average of 50 % of internalization at the higher concentration. 
The behavior of the double systems DF3-TPP and DF3-RGD, 
with a notable decrease of internalization versus the double DF3 
and DF4, even worse than the single agents S3 and S4, showed 
that the introduction of nonspecific moieties in the system could 
interfere with the binding properties of the benzylguanidine 
group and into the recognition process with the NET. These data 
made the authors to stake out the final aim of the work and 
focus their efforts on obtaining the best benzylguanidine based 
Y shape multivalent ligand applicable as vectorization agent for 
NB. For this aim, studies about the influence of the length and 
flexibility of the scaffold on their uptake properties were carried 
out for the following F-PEGylated double ligands families 
classified according with their rigid or flexible nature and their 
length (Figure 1 and Figure 2 a): Double rigid (DR3, DR4), 
Double flexible small (DFS3, DFS4), Double flexible (DF3, DF4), 
and double flexible large (DFL3, and DFL4). 
Double Rigid scaffolds (DR) are based on aromatic core body. 
They were synthetized by amide formation coupling reaction 
with same starting material described for single analogues 
connecting two units of S3 and S4 with terminal alkyl amine 
group with isophthalic acid analogue for affording the 
homogeneous DR3 and DR4, respectively. (See SI Scheme S7 
and S8). Double Flexible ligands (DF) are based on the 
presence of an oligopeptidic chain. Among this group, three 
different types of flexible structures were synthesized according 
with their lengths, presenting one, two and up to three amino 
acids, DFS, DF, DFL, respectively. Briefly, these DF analogues 
were synthesized by coupling amidebezylguanidine analogues 
in meta- and para- conformation (S3 and S4) through a peptide 
chain, affording DFS3 and DFS4, with one amino acid in the 
structure, DF3 and DF4 with two amino acids, and DFL3 and 
DFL4, with three amino acids conferring more flexibility and 
distance between the binding points with the increase of units in 
the scaffold structure. DF ligands were synthetized through 
typical solid phase peptide synthesis, by conventional Fmoc 
deprotection/HOBT-based acid activation coupling starting from 
Fmoc-NH-Lys-NH-Mtt Wang resin. The rest of amino acids, as 
well as the targeting agents previously synthetized in this case 
with terminal carboxylic acid group proportioned by succinic acid 
coupling with the corresponding initial analogue S3 and S4 (See 
SI from Scheme S9 to S11 and Scheme S6), were consecutively 
coupled. Finally, the complete systems were released from the 
resin by the addition of TFA cocktail. In vitro experiments for 
internalization in NB cells, were carried out by screening the 
PEGylated and fluorescein marked analogues for each family at 
12.5 µg/ml and 6.5 µg/ml following conditions previously 
described. The analogues analyzed were: S3 and S4, as 
references, plus, rigid ligands DR3 and DR4, and finally from 
flexible scaffolds, DFS3, DFS4, DF3, DF4 and both DFL3 and 
DFL4.  
Figure 2. a) Calculated distance by molecular mechanics (MM2) calculations 
between recognition spots in the double scaffolds structures DR4 (7 Å), DFS4 
(4 Å), DF4 (8 Å) and DFL4 (16.9 Å), NOTE: The distances are equivalent in 
the case of meta-substituted systems b) Initial screening of single (S3 and S4) 
versus double ligands for uptake in NB cells at low concentrations, 12.5 
µg.mL-1  (blue)  and 6.25 µg.mL-1 (red). 
As Figure 2. b shows, the act of doubling the number of 
targeting moieties did not govern the entire uptake process. 
Moreover instead of number of targeting agent, their disposition, 
their distance to each other and their freedom to adopt cluster 
configuration in their interaction with the receptor in the cell 
membrane seemed determinant. Thus, the effect of the structure 
and length of the scaffold has a dominant effect in order to 
interact with the NET of the NB cell membrane. Taking as an 
example the data for the meta-derivate, double rigid scaffold 
DR3 improved the internalization properties in front of its 
corresponding single counterpart S3 barely at same scale to 
flexible analogues DF3. This equal behavior  may be explained 
by the duplication of the interaction points with NET in both 
analogues, further they present equal distance between 
recognition points following MM2 calculations (DR3 (7 Å), DF7 
(8 Å)) .  Thus, in this case, the effect in the uptake process is 
governed by the duplication of targeting agent. On the other 
hand, the larger and more flexible analogue, DFL3 (16 Å, of 
distance between recognition points)), resulted significantly the 
more efficient in the uptake process compared to S3 and the 
rest of the ligands in the family. Thus, the fact of having two 
benzyl guanidine derivate in the same system sharpens when  
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Figure 3. a) Upper panel, Graphic shows relative fluorescent signal (tumor area/whole mouse) obtained from xenograft neuroblastoma-inoculated mice 72h after 
injection with either NP-NH2, NP-PEG-DFL3, or NP-PEG-DFL4 (mean+SD; n=3-5 per group); lower panel  b) Representative photographs of xenograft mice 
treated as in a), showing luminescent tumor signal (upper panels) and fluorescent nanoparticle signal (lower panels) 
 
the distance between the recognition moieties is the barely three 
amino acids and the system is flexible. 
 Para analogues from Figure 2a kept a similar behavior, when 
the distance is about  16.9 Angstrom (DFL4) the internalization 
folds up around 3 times versus their double more rigid (DR4) 
and flexible shorter families (DF and DFS) counterparts. This 
fact gave light for understanding the behavior of the targeting 
ligand. The distance and the flexibility of the ligand allow the 
system to work such as, common bio- receptor with double 
anchoring point, and if the distant and flexibility of the ligand is 
not appropriate the double ligand works such as single targeting 
agent interacting with only one of the recognitions points present 
in the scaffold. Thus, comparing the uptake properties of the 
best bi-functional system (DFL4) with the best mono-functional 
(S4) we can conclude that for 100 % of internalization in NB cell, 
DFL4 analogue needs 10 times less concentration than S4. 
Once known the behavior in terms of cell uptake, the next step 
to corroborate the characteristics of these systems, was to study 
the selective transporting and accumulation of significate 
payload (drugs, nanoparticles or even image agents) to the 
neuroblastoma tumoral environment. To achieve this goal, we 
conducted in vivo experiments to compare ligands with the best 
performance in vitro (i.e. DFL3 and DFL4) versus a non-targeted 
system. To this end, mesoporous silica nanoparticles (MSN´s) 
marked with Cy7 were synthetized and surface-functionalized 
with the corresponding vectorization agents, through a PEG 
linker chain affording the control naked material NP-NH2 and the 
targeted nanoparticles NP-PEG-DFL3 and NP-PEG-DFL4. 
Previous results of our group have shown that MSN´s are highly 
efficient nanotransporters for drug delivery, due to their optimal 
loading and controlled release properties. Additionally, MSN´s 
may be easily functionalized for adding vectorization agents.[20–
22]. Cy7 is a near infrared marker frequently used for in vivo 
assays, given the reduced tissue auto fluorescence at this 
wavelength. This characteristic makes Cy7 a suitable candidate 
to label the nano-transporters for their in vivo evaluation. We 
carried out functionalization of the agents to the nanoparticle´s 
surface through a PEG linker; PEG confers more ability in 
dispersion and helps to abolish the opsonization process which 
may prolong circulation time in the blood stream.[23] We 
subcutaneously implanted human neuroblastoma NB1691-luc 
cells (2x106 cells/mouse) into the flank of immuno-deficient NGS 
mice (NOD/SCID deficient in the common gamma chain). These 
cells constitutively express Luciferase, which allows in vivo 
monitoring of tumor growth by bioluminescence quantification 
upon injection of Luciferase substrate Luciferin (1,25 mg/mouse). 
Thus, three weeks after cell inoculation we assessed tumor 
development in mice, and sorted mice into three groups with a 
homogeneous distribution of tumor size among them (3-5 
specimens per group (see Figures S9 and S10 in SI). Mice 
received intravenous injections of 1 mg of NP-NH2, NP-PEG-
DFL3, or NP-PEG-DFL4 in 0.2 mL of saline solution. In order to 
evaluate system accumulation in the tumor mass in each case, 
we quantified fluorescent signal ratio of Cy7 in tumor area vs. 
the whole mouse, at 72 hours after system administration. As 
shown in Figure 3, we observed preferential accumulation of 
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targeted MSN´s systems (NP-PEG-DFL3 and NP-PEG-DFL4) in 
tumor mass, which was detected by bioluminiscence. In 
conclusion, this work has allowed the selection of a novel 
system based on a Y-shape multivalent double ligand targeting 
for NB with a specific composition and length .  Their behavior in 
terms of selectivity and efficacy for improving cell internalization 
and in vivo accumulation in neuroblastoma xenografts have 
been evaluated. These new Y-shape double system presents a 
substantial improvement in cell uptake in vitro, 20-times higher 
than the single-targeted system and an effective accumulation in 
tumor mass in vivo. Further, they are easily tunable for using as 
versatile targeting system for drug delivery in conjugates or 
nano-transporters, as well as for imaging agents. Our findings 
may pave the way for rising the efficacy against NB in terms of 
diagnosis or treatment. 
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